Inventor
Shuichan Xu
Inventor
San Diego, CA, US
Overview
Patents· 18 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
A61Kprimary
A61KPreparations for medical, dental or toiletry purposes33%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations33%
C07DHeterocyclic compounds20%
C12QMeasuring or testing processes involving enzymes, nucleic acids or microorganisms7%
G01NInvestigating or analysing materials by determining their chemical or physical properties5%
Y10STechnical subjects covered by former uspc cross-reference art collections [xracs] and digests2%
PatentTitleYear
10,646,493Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith202010,576,085Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith202010,004,735Methods for treating cancer using TOR kinase inhibitor combination therapy comprising administering substituted pyrazino[2,3-b]pyrazines20189,980,963Treatment of cancer with dihydropyrazino-pyrazines20189,937,170Treatment of cancer with TOR kinase inhibitors20189,795,607'Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith'20179,737,535'Methods for treating cancer using TOR kinase inhibitor combination therapy comprising administering substituted pyrazino[2,3-b]pyrazines'20179,737,541'Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith'20179,623,028'Methods of treating a cancer using substituted pyrrolopyrimidine compounds, compositions thereof'20179,557,338'Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for tor kinase inhibitory activity'20179,555,033'Identification of LKB1 mutation as a predictive biomarker for sensitivity to TOR kinase inhibitors'20179,512,124'Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith'20169,505,764'Treatment of cancer with dihydropyrazino-pyrazines'20169,493,466'Treatment of cancer with TOR kinase inhibitors'20169,428,509'Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith'20169,375,443'Method for treating advanced non-small cell lung cancer (NSCLC) by administering a combination of a TOR kinase inhibitor and azacitidine or erlotinib'20169,346,812'Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith'20169,155,736'Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity'2015Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
2015–2020Patents assigned to SIGNAL PHARM LLC (18)· patent assignee history
2015–2020Based in San Diego, CA, US· patent location history
2016–2017Patents assigned to SIGNAL PHARMACEUTICAL LLC (3)· patent assignee history
2017Patents assigned to CHOPRA RAJESH (1)· patent assignee history
2017Patents assigned to NING YUHONG (1)· patent assignee history
2017Patents assigned to SANKAR SABITA (1)· patent assignee history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| SIGNAL PHARM LLC | 18 | 2015–2020 |
| SIGNAL PHARMACEUTICAL LLC | 3 | 2016–2017 |
| CHOPRA RAJESH | 1 | 2017 |
| NING YUHONG | 1 | 2017 |
| SANKAR SABITA | 1 | 2017 |
Locations
| Location | Patents | Span |
|---|---|---|
| San Diego, California, US | 18 | 2015–2020 |